Meta-analysis of the efficacy and safety of Yangxue Qingnao Granule and nimodipine in the treatment of chronic cerebral circulation insufficiency*
2019, 42 (6):
Objective To evaluate the efficacy and safety of Yangxue Qingnao Granule and nimodipine in the treatment of chronic cerebral circulation insufficiency.Methods The databases of CNKI, Wanfang, VIP, CMB, PubMed, The Cochrane library and Embase were searched, and the randomized controlled trials (RCT) of Yangxue Qingnao Granule group and nimodipine group for the treatment of chronic cerebral circulation insufficiency were collected.Two researchers conducted literature screening and literature quality evaluation according to the inclusion and exclusion criteria and the “risk of bias assessment tool” of the Cochrane collaboration. Then, the included RCT studies were meta-analyzed using RevMan 5.3 software.Results A total of 1 457 patients were included in 18 RCT studies, including 744 patients in the Yangxue Qingnao Granule group and 713 patients in the nimodipine group. Meta analysis results show that the Yangxue Qingnao Granule group total effective rate is better than that of nimodipine group (OR = 4.88, 95% CI [3.63, 6.55], P<0.000 01), and total effective rates of Yangxue Qingnao Granule group for the treatment of chronic cerebral circulation insufficiency in a month (OR = 4.52, 95% CI [3.30, 6.19], P<0.000 01) and 3 months (OR=8.24, 95% CI [3.45, 19.67], P<0.000 01) were superior to those of nimodipine group. Compared with the nimodipine group, the Yangxue Qingnao Granule group was able to effectively reduce the fibrinogen (MD=1.07, 95%CI [0.84, 1.30], P<0.00001) and the plasma viscosity ratio index (MD=0.34, 95%CI [0.30, 0.37], P<0.000 01).Conclusion Yangxue Qingnao Granule is better than nimodipine in treating patients with chronic cerebral circulation insufficiency. Due to the limitations of the quality and quantity of included studies and the lack of standard experimental design, the above conclusions still need to be verified by high-quality, large-sample and multi-center clinical studies.
Related Articles |